Tranexamic Acid Benefit in Traumatic Brain Injury
Patient Selection Criteria for TXA Benefit
- The American College of Surgeons recommends that mild-to-moderate traumatic brain injury patients treated within 3 hours of injury with tranexamic acid (TXA) can reduce head injury-related death by 22% (RR 0.78, 95% CI 0.64-0.95) 1
- Patients with both pupils reactive at baseline demonstrated cost-effective mortality reduction 1, 2
- Earlier treatment is more effective: patients treated within 1 hour had 65% lower 30-day mortality (HR 0.35, 95% CI 0.19-0.65) 1
Critical Timing Considerations
- Treatment benefit decreases by approximately 10% for every 15-minute delay 3
- Early treatment (within 1 hour) showed the greatest relative risk reduction in mild-to-moderate TBI (p=0.005 for time-to-treatment effect) 1
- Treatment after 3 hours may increase mortality risk and is not recommended 1, 3
Dosing Protocol
- The standard dosing protocol endorsed by multiple guidelines is a loading dose of 1 g IV over 10 minutes, followed by a maintenance dose of 1 g IV infusion over 8 hours 3, 4, 5
Implementation Pitfalls to Avoid
- Delaying administration for diagnostic workup can reduce TXA effectiveness, and it is recommended to give TXA empirically before viscoelastic testing or advanced imaging if clinical suspicion exists 4, 5
- Treating severe TBI patients (GCS 3, bilateral unreactive pupils) does not provide benefit and resources may be better allocated elsewhere 1
- Administering TXA beyond 3 hours may actually increase mortality and should be avoided 1, 3
Tranexamic Acid Administration in Traumatic Brain Injury
Critical Timing and Dosing Considerations
- Treatment with tranexamic acid after 3 hours may increase the risk of death due to bleeding (RR 1.44, 95% CI 1.12-1.84) 6
- The standard regimen for tranexamic acid includes a loading dose of 1 g IV over 10 minutes, followed by a maintenance infusion of 1 g IV over 8 hours, and must be initiated within 3 hours of injury 6
- Pre-hospital administration of tranexamic acid should be considered to ensure treatment within the critical 1-hour window 6
Cost-Effectiveness
- Tranexamic acid is highly cost-effective for mild and moderate TBI, with a cost per life-year gained ranging from $48 in low-income countries to $64 in high-income countries 6